预约演示

更新于：2026-04-03

Sorafenib Tosylate

甲苯磺酸索拉非尼

更新于：2026-04-03

概要

基本信息

药物类型

小分子化药

别名

N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea、SORAFENIB、Sorafenib tosilate

+ [16]

靶点

BRAF x CRAF x FLT3 x PDGFRβ x RET x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit

作用方式

抑制剂、拮抗剂

作用机制

BRAF抑制剂(丝氨酸/苏氨酸蛋白激酶B-raf抑制剂)、CRAF抑制剂(C-Raf激酶抑制剂)、FLT3抑制剂(酪氨酸蛋白激酶受体FLT3抑制剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [3]

在研适应症

甲状腺癌不可切除的肝细胞癌晚期肝细胞癌+ [10]

非在研适应症

腺泡细胞癌急性双表型白血病急性白血病+ [142]

原研机构

Onyx Pharmaceuticals, Inc.

在研机构

Novartis Pharmaceuticals Canada, Inc.

Merck Sharp & Dohme Corp.

复旦大学

+ [10]

非在研机构

Bristol Myers Squibb Co.

Amgen, Inc.

Sanofi

+ [16]

权益机构

Amgen, Inc.

拜耳医药保健有限公司

Onyx Pharmaceuticals, Inc.

+ [4]

最高研发阶段批准上市

首次获批日期

美国 (2005-12-01),

晚期肾细胞癌

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C28H24ClF3N4O6S

InChIKeyIVDHYUQIDRJSTI-UHFFFAOYSA-N

CAS号475207-59-1

关联

863

项与甲苯磺酸索拉非尼相关的临床试验

ChiCTR2600120015

/ Not yet recruitingN/AIIT

Single-Center Prospective Study of Homoharringtonine Combined with Azacitidine and Venetoclax in the Treatment of Adult Patients with Newly Diagnosed Acute Myeloid Leukemia

开始日期2026-03-08

申办/合作机构

中国医科大学附属第一医院

NCT06227221

/ Not yet recruiting临床2期IIT

A Phase 2, Randomized, Placebo Controlled Study Investigating the Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus

The purpose of this study is to investigate the therapeutic effect and safety of Sorafenib in T1DM patients.

开始日期2026-02-01

申办/合作机构

中南大学湘雅三医院

NCT07264010

/ Not yet recruiting临床2/3期IIT

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for Measurable Residual Disease Persisting Acute Myeloid Leukemia: a Prospective, Single-arm, Multicenter Clinical Study

The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.

开始日期2025-12-01

申办/合作机构

南方医科大学南方医院

100 项与甲苯磺酸索拉非尼相关的临床结果

登录后查看更多信息

100 项与甲苯磺酸索拉非尼相关的转化医学

登录后查看更多信息

100 项与甲苯磺酸索拉非尼相关的专利（医药）

登录后查看更多信息

12,118

项与甲苯磺酸索拉非尼相关的文献（医药）

2026-12-31·ANNALS OF MEDICINE

Molecular targeted therapy in combination with chemotherapy for the treatment of platinum-resistant/refractory ovarian cancer (PROC): a systematic review and network meta-analysis

Review

作者: E., Shaolong ; Ying, Tianshu ; Ying, Huanchun

BACKGROUND:

Although single-agent chemotherapy is the most common approach for treating platinum-resistant or refractory ovarian cancer (PROC), there is growing evidence that combining molecular targeted agents with chemotherapy is beneficial, especially for certain patient groups. However, the most effective combination regimen remains elusive.

OBJECTIVES:

This Bayesian network meta-analysis (NMA) aims to identify the best combination therapy for PROC.

METHODS:

Relevant studies were searched in PubMed, EMBASE, Web of Science and the Cochrane Central Register of Controlled Trials from their inception until October 2024. The primary outcomes were overall survival (OS), progression-free survival (PFS) and adverse events (AEs). Statistical analyses were performed using the GEMTC package (1.0-2) and R 4.2.0. This review was registered in PROSPERO (CRD42023428414).

RESULTS:

Our analysis of 22 randomized controlled trials (RCTs) (n = 3408) demonstrated that chemotherapy combinations with bevacizumab (hazard ratio (HR) = 0.52-0.65), sorafenib (HR = 0.65, 95% confidence interval (CI): 0.45-0.93) or adavosertib (HR = 0.56, 95%CI: 0.35-0.90) significantly improved OS and PFS versus chemotherapy alone. Notably, adavosertib + gemcitabine was associated with an increased risk of grade 3-4 AEs (relative risk (RR) = 1.8, 95%CI: 1.3-2.7), but these were generally manageable.

CONCLUSIONS:

Bevacizumab-based combinations demonstrate consistent benefits across multiple regimens for PROC. Paclitaxel + bevacizumab emerges as the optimal balance of efficacy and safety. Topotecan + sorafenib could be an alternative for patients who are ineligible for anti-angiogenic therapy.

2026-12-01·FUNCTIONAL & INTEGRATIVE GENOMICS

Overexpression, clinical significance and potential mechanisms of protein kinase D1 in hepatocellular carcinoma: multi-omic analyses and pharmacological insights

Article

作者: He, Rong-Quan ; Huang, Zhi-Guang ; Chen, Zhen-Dong ; Dang, Yi-Wu ; Deng, Yu-Long ; Wei, Xi-Ni ; Zhu, Liang-Qin ; Yang, Min-Ying ; Chen, Gang ; Wu, Ke-Jun ; He, Fei-Yan ; Zhan, Yan-Ting ; Qin, Kai ; Tang, Yu-Xing ; Lu, Hui-Ping

Protein kinase D1 (PRKD1), a serine/threonine kinase of the PKD family, has been implicated in tumor biology, but its role in hepatocellular carcinoma (HCC) remains unclear. We explored PRKD1 expression and function using immunohistochemistry, bulk and single-cell RNA sequencing, and in vitro functional assays. PRKD1 protein levels were significantly elevated in 339 HCC tissues compared to corresponding adjacent non-tumorous samples (11.390 ± 1.560 vs. 6.277 ± 2.357, P < 0.0001). Multicenter bulk transcriptomic data confirmed consistent PRKD1 mRNA overexpression (SMD = 0.26, 95% CI = 0.14-0.39), with single-cell transcriptomic profiling indicating specific enrichment in endothelial cells, smooth muscle cells, and hepatocytes. High PRKD1 expression was associated with advanced tumor stages and worse overall survival. Functionally, PRKD1-associated genes were enriched in extracellular matrix and focal adhesion pathways. Immune profiling revealed positive correlations with M2 macrophages, regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs), and negative correlations with CD8⁺ T cells and CD4⁺ Th1 cells, suggesting an immunosuppressive role. Mechanistic experiments demonstrated that conditioned medium from PRKD1-knockdown HCC cells promoted M1 polarization and reduced M2 markers in THP-1 cells, while PRKD1 silencing increased PD-L1 and IDO1 expression. In contrast, IFN-γ treatment did not induce PRKD1 expression, indicating that PRKD1 actively contributes to, rather than responds to, immunosuppressive cues. PRKD1 knockdown markedly impaired HCC cell proliferation and migration. Pharmacologically, nitidine chloride significantly reduced PRKD1 expression in a dose-dependent manner, and molecular docking suggested a potential direct interaction. With respect to drug response, PRKD1-high HCC cases exhibited increased predicted sensitivity to multiple tyrosine kinase inhibitors (TKIs), while in vitro PRKD1 knockdown reduced sorafenib sensitivity, and sorafenib treatment suppressed both PRKD1 and p-ERK1/2 levels. Collectively, our findings identify PRKD1 as a multifaceted contributor to HCC progression, immune microenvironment modulation, and TKI responsiveness. These results highlight PRKD1 as a promising therapeutic target warranting further mechanistic and translational investigation.

2026-06-01·BIOORGANIC CHEMISTRY

Targeting VEGFR-2 with piperazine bridged indolin-2-one derivatives

Article

作者: Tan, Oya Unsal ; Arafa, Reem K ; Zengin, Merve ; Küçükkılınç, Tuba Tüylü

As a key mediator of tumor angiogenesis, VEGFR-2 has emerged as a promising therapeutic target for combating cancer. In the present study, a series of 6-substituted-3-(4-(4-(substitutedphenyl/benzyl)piperazin-1-yl)benzylidene) indolin-2-one derivatives (2-24) were synthesized in good yields and structurally confirmed by IR, NMR, and HRMS analyses. Several compounds exhibited strong VEGFR-2 inhibition, with activities comparable to or exceeding that of sorafenib, but lower than sunitinib. Cytotoxicity assays against MCF-7 breast cancer cells revealed five derivatives (4, 7, 9, 10, and 12) more active than doxorubicin along with five additional compounds showing comparable potency. In contrast, the compounds displayed moderate cytotoxic activity against the MDA-MB-231 cell line and none showed significant toxicity toward MCF-10A normal breast epithelial cells. Mechanistic studies of compound 10 demonstrated G0/G1 phase arrest, apoptosis induction, and increased ROS generation, suggesting its potential as a selective and effective lead for breast cancer therapy.

1,585

项与甲苯磺酸索拉非尼相关的新闻（医药）

2026-04-02

·Firstwordpharma

AstraZeneca touts quadruplet approach in earlier-stage liver cancer

AstraZeneca said a treatment regimen anchored by its PD-L1 inhibitor Imfinzi (durvalumab) and anti-CTLA-4 antibody Imjudo (tremelimumab) succeeded in the Phase III EMERALD-3 trial in patients with hepatocellular carcinoma (HCC).The study is seen as an important test of whether using every available treatment strategy right from the start can improve outcomes for liver cancer patients, though some key opinion leaders (KOLs) worry such an aggressive approach may be too harsh for routine practice and could leave patients with fewer treatment options later on.EMERALD-3 includes 760 patients with unresectable, locoregional HCC who are eligible for embolisation. Participants received either the STRIDE regimen – consisting of single-dose Imjudo plus regular-interval Infinzi – with transarterial chemoembolisation (TACE); the same immunotherapy backbone plus Eisai's VEGF receptor inhibitor Lenvima (lenvatinib) and TACE; or TACE alone.Eye on OSAstraZeneca said the quadruplet approach achieved significant and clinically meaningful improvement on the primary endpoint of progression-free survival (PFS), compared to TACE alone. Overall survival (OS), a key secondary endpoint, showed a trend in favour of this combination as well, but data are still immature.Although it hasn't yet been formally tested, AstraZeneca said early data from the treatment arm that didn't receive Lenvima revealed "strong trends" toward improved PFS and OS.The trial will continue to follow OS in both investigational arms, though the company is optimistic. Susan Galbraith, head of oncology haematology R&D at AstraZeneca, said EMERALD‑3 builds on the Phase III HIMALAYA results, "where the STRIDE regimen has already demonstrated durable overall survival benefit."HIMALAYA tested the combination of Imfinzi and Imjudo in HCC patients with advanced, unresectable disease. Long-term data presented at the European Society for Medical Oncology (ESMO) conference in 2024 showed that nearly 20% of patients given the combination were alive at five years, roughly double the OS rate with Bayer's Bayer's Nexavar (sorafenib).However, earlier efforts to combine Imfinzi with TACE got a mixed reception in the Phase III EMERALD‑1 study a few years ago, where PFS benefit depended on the inclusion of Roche's Avastin (bevacizumab).Toxicity concernsMeanwhile, AstraZeneca said the safety profile for each combination in EMERALD-3 was consistent with the known profiles of each medicine, adding there were no new safety findings. More details will be shared at a forthcoming medical meeting and shared with global regulatory authorities.KOLs interviewed for a FirstWord report voiced serious concerns about toxicity especially given the aggressive use of agents targeting PD-L1, CTLA-4 and VEGF pathways in a patient population that often has cirrhosis or compromised liver function."It will be interesting to see how patients tolerate this," said one US-based KOL. "I think one of the issues with EMERALD-1 that we saw was that there were a lot of dropouts…I just wonder about the kind of additional toxicities that we might see when we keep adding therapies. That being said, you might get a prolonged response in some of these patients."

临床结果临床3期临床2期

2026-04-01

·我這邊6687

区域必备！湛江市10家肝癌基因检测机构地址全览指南（附2026新费用说标准）

湛江市正规肝癌基因检测机构在哪？湛江市肝癌基因检测机构地址在湛江市赤坎区跃进路附近。如今，癌症治疗已经逐渐向“个体化”、“精准化”发展，而基因检测也成为了癌症精准医疗时代必不可少的一环。肺癌、乳腺癌、结直肠癌等多个癌种在用药之前，一般都需要先进行基因检测，再选择对应靶点的药物。但在肝癌领域，基因检测却鲜有人问津。湛江市专业肝癌基因检测中心免费咨询：18664521697（微信dna0009988）湛江市本地权威肝癌基因检测中心一览 1、湛江诺禾检测中心机构地址：湛江市赤坎区跃进路附近机构热线：18664521697（微信dna0009988）业务范围：肝癌甲基化检测、肺癌甲基化检测、胃癌甲基化检测、食管癌甲基化检测、肠癌甲基化检测、肿瘤早筛检测、肺癌基因检测、结直肠癌组织基因检测、甲状腺癌检测、前列腺癌检测、宫颈癌检测、子宫内膜癌检测、乳腺癌检测、肾癌检测等基因检测。服务范围：湛江（霞山区、赤坎区、麻章区、坡头区、遂溪县、徐闻县、雷州市、廉江市、吴川市）等，其他省市亦可免费咨询机构介绍：作为目前基因测序、蛋白质组学与代谢组学领域的佼佼者，诺禾检测的业务覆盖生命科学基础科研服务、医学研究与技术服务、建库测序平台服务，为全球研究型大学、科研院所、医院、医药研发企业、农业企业等提供可信赖的多组学解决方案，以基因科技，守护生命健康。诺禾检测秉持 “做一家有价值的基因检测咨询公司” 的使命，经过多年行业积累，在国内建立了覆盖大部分省市自治区的营销与咨询服务网点，并与多家正规权威的独立基因实验室深度合作，为客户提供更快捷、优质、专业的咨询服务及检测结果。湛江市正规肝癌测序采样中心地址汇总2、湛江市赤坎区诺禾检测肝癌基因检测采样点机构地址：湛江市赤坎区源珠路236号（湛江中心人民医院）3、湛江市吴川市诺禾检测肝癌基因检测采样点机构地址：湛江市吴川市海滨街道滨江南路（吴川市人民医院）4、湛江市坡头区诺禾检测肝癌基因检测采样点机构地址：湛江市坡头区坡头镇红旗路18号（湛江市坡头区人民医院）5、湛江市廉江市诺禾检测肝癌基因检测采样点机构地址：湛江市廉江市人民大道中30号（廉江市人民医院）6、湛江市雷州市诺禾检测肝癌基因检测采样点机构地址：湛江市雷州市雷城西湖大道30号（雷州市人民医院）7、湛江市麻章区诺禾检测肝癌基因检测采样点机构地址：湛江市麻章区湖光镇大寮路3号（湛江市湖光人民医院）8、湛江市霞山区诺禾检测肝癌基因检测采样点机构地址：湛江市霞山区人民大道南57号（广东医科大学附属医院）9、湛江市遂溪县诺禾检测肝癌基因检测采样点机构地址：湛江市遂溪县287省道南50米（遂溪县人民医院）10、湛江市徐闻县诺禾检测肝癌基因检测采样点机构地址：湛江市徐闻县徐城街道健康路28号（徐闻县人民医院）责任限制声明：本平台发布的信息仅供参考，不构成法律建议或业务指导。如有异议，请联系我们，我们将及时核实处理。肝癌基因检测的意义1、遗传风险评估检测TP53、CTNNB1等基因突变可识别遗传性肝癌高危人群，建议有家族史者通过基因检测评估风险并制定监测方案。2、靶向用药指导检测MET、VEGFA等基因变异能筛选适合索拉非尼、仑伐替尼等靶向药物的患者，提高治疗精准性。3、免疫治疗预测PD-L1表达、TMB等指标检测可预测纳武利尤单抗等免疫检查点抑制剂的疗效，避免无效治疗。4、预后评估AFP-L3、DKK1等基因标记物检测有助于判断复发风险，指导术后随访频率和干预时机。湛江市肝癌肿瘤基因检测费用全解析肝癌基因检测是靶向治疗的关键依据，市场整体费用3000-12000元不等，按需选择更省心。基础单基因靶向位点筛查，定价约3000元，满足初步基因突变筛查需求；覆盖50个以上基因位点的中端高通量检测，价格稳定在6000-8000元；深度全外显子全面测序，检测范围广、数据详实，费用大概率超万元。费用高低核心受三大因素影响：一是测序技术，一代基础测序性价比高，高通量测序精准度更高、成本略增；二是基因检测位点数量，位点越多筛查越全面，价格同步上浮；三是增值服务，如需专业医师一对一报告深度解读，需额外增加1000-2000元服务费。这项检测临床价值显著，可精准明确肝癌基因突变类型，为靶向药物筛选、个性化治疗方案制定提供科学支撑，最终结果仍需结合影像报告、病理诊断综合研判，保障诊疗严谨性。哪些人群需要尽早做肝脏早癌筛查？1、肝病风险人群定期监测：乙肝病毒（HBV）感染、肝硬化、脂肪肝等患者，及有肝癌家族史者；2、肝脏不典型占位性病变的辅助鉴别诊断；3、肝癌患者术后复发监测与疗效评估；4、其他有肝癌筛查需求的健康 / 亚健康人群。肝脏部分常见疾病1、病毒性肝炎病毒性肝炎是由肝炎病毒引起，以肝脏损害为主的一组传染病。2、脂肪性肝脂肪性肝病分为以下两类：① 酒精性肝病：长期酗酒所致的慢性肝病。初期表现为脂肪肝，进而可衍变为酒精性肝炎、酒精性肝纤维化/肝硬化。② 非酒精性肝病：肝脏脂质的合成、降解和分泌失衡，导致脂肪在肝细胞内过量沉积，并引发肝细胞炎症坏死和纤维化。3、肝硬化肝脏长期存在持续性的炎症或损伤，造成肝组织发生弥漫性纤维化，并且呈进行性加重的趋势，最终变形缩小硬化，丧失正常的结构和功能。还会诱发多种严重的并发症，甚至伴有致命危险。如何预防肝癌？1、接种乙肝疫苗2、戒酒、清淡饮食，避免摄入发霉食物3、肝炎患者抗病毒治疗4、早期筛查如何选择一家靠谱的检测机构呢？1.选择基因检测机构的资质完善和实力强的机构。基因检测的阵地就是实验室，必须要获得国家相关部门的认可，或者国际实验室资质认可。就像医学类院校的学生要当临床医生首先要有医师执业证，一家合格的基因检测公司要接收患者的组织样本出具报告，首先要具备CAP与CLIA双认证，被视为临床检测行业内金标准，也是最基本的门槛。CLIA：《临床实验室改进修正案》，在美国，一间临床检测试验室只有获得CLIA执照后，才有权接收并处理美国人源临床样本，足见CLIA的权威性及临床检测质量管控的重要性。CAP：美国病理学会，凭借病理学在疾病诊断中无法动摇的金标准地位，对CLIA提出了自己的解读，CAP制定了具有可操作性的质量评价规程和认证体系。因此大家在选择基因检测公司的时候尽量选择知名的，专注于癌症基因领域的大公司。2.考察机构的数据分析及报告解读能力。整个流程中，最关键的环节是数据分析，需要庞大的数据库及权威的分析团队，包括分子生物学专家、病理医生，肿瘤医生、生物信息学专家、免疫学专家等通力合作，针对每一个突变位点查阅文献，相似病历，找到最匹配的治疗药物，和前沿药物临床试验，这样才能为癌症患者出一份精准的基因检测报告。很多晚期无路可走的患者，甚至通过权威基因检测报告推荐的临床试验获得了生机。晚期癌症患者基因检测无靶向药，但却获得了更好的治疗！湛江市肝癌基因检测哪里可以做？湛江市赤坎区跃进路附近的湛江市肝癌基因检测中心就可以做肝癌基因检测。从分子层面认识肝癌，基因检测开启全新可能。它让早诊更早、治疗更准、预后更优，也为新药研发提供靶点。技术在进步，希望在生长，肝癌终将从 “难治” 走向 “可防可治”，照亮更多患者的生命之路。

上市批准核酸药物

2026-04-01

·我這邊6687

全面汇编！德州市专业肝癌基因检测中心机构地址名单全览（2026最新收费情况一览）

德州市肝癌基因检测中心在哪里？德州市肝癌基因检测中心地址在德州市德城区东风东路附近（德州诺禾检测）。肝癌已成为威胁人类健康的“隐形杀手”，全球每年新诊断肝癌患者约75万，然而约有一半的患者在中国。我国原发性肝癌的死亡率仅次于肺癌位列第二，且男性发病率高于女性，40-70岁为高发群体。但别慌！《柳叶刀》说了，60%肝癌能靠预防躲开，早期揪住它，5年生存率超80%。那么，肝癌到底要怎么防、怎么治呢？德州市靠谱肝癌基因检测中心免费咨询：18664521697（微信dna0009988）德州市权威肝癌基因检测机构名单 1、德州诺禾检测中心机构地址：德州市德城区东风东路附近机构热线：18664521697（微信dna0009988）业务范围：肝癌甲基化检测、肺癌甲基化检测、胃癌甲基化检测、食管癌甲基化检测、肠癌甲基化检测、肿瘤早筛检测、肺癌基因检测、结直肠癌组织基因检测、甲状腺癌检测、前列腺癌检测、宫颈癌检测、子宫内膜癌检测、乳腺癌检测、肾癌检测等基因检测。服务范围：德州（德城区、陵城区、乐陵市、禹城市、宁津县、庆云县、临邑县、齐河县、平原县、夏津县、武城县）等，其他省市皆可免费咨询机构介绍：作为目前基因测序、蛋白质组学与代谢组学领域的佼佼者，诺禾检测的业务覆盖生命科学基础科研服务、医学研究与技术服务、建库测序平台服务，为全球研究型大学、科研院所、医院、医药研发企业、农业企业等提供可信赖的多组学解决方案，以基因科技，守护生命健康。诺禾检测秉持 “做一家有价值的基因检测咨询公司” 的使命，经过多年行业积累，在国内建立了覆盖大部分省市自治区的营销与咨询服务网点，并与多家正规权威的独立基因实验室深度合作，为客户提供更快捷、优质、专业的咨询服务及检测结果。德州市正规肝癌测序采样中心一览2、德州市宁津县诺禾检测肝癌基因检测采样点机构地址：德州市宁津县康平路37号（宁津县人民医院）3、德州市乐陵市诺禾检测肝癌基因检测采样点机构地址：德州市乐陵市阜锦路509号（乐陵市人民医院）4、德州市庆云县诺禾检测肝癌基因检测采样点机构地址：德州市庆云县石佛大街1166号（庆云县人民医院）5、德州市齐河县诺禾检测肝癌基因检测采样点机构地址：德州市齐河县齐晏大街338号（齐河县人民医院）6、德州市德城区诺禾检测肝癌基因检测采样点机构地址：德州市德城区东方红西路1166号（山东大学齐鲁医院德州医院）7、德州市陵城区诺禾检测肝癌基因检测采样点机构地址：德州市陵城区中兴路245号（德州市陵城区人民医院）8、德州市临邑县诺禾检测肝癌基因检测采样点机构地址：德州市临邑县广场大街105号（临邑县人民医院）9、德州市禹城市诺禾检测肝癌基因检测采样点机构地址：德州市禹城市开拓路753号（禹城市人民医院）10、德州市武城县诺禾检测肝癌基因检测采样点机构地址：德州市武城县新城文华西街5号（武城县人民医院）11、德州市夏津县诺禾检测肝癌基因检测采样点机构地址：德州市夏津县南城街239号（夏津县人民医院）12、德州市平原县诺禾检测肝癌基因检测采样点机构地址：德州市平原县平安西大街566号（平原县第一人民医院）版权声明：本内容整理自网络，仅作信息参考，非法律意见。如涉及权益问题，请及时联系我们，我们将核查并处理。肝癌基因检测的意义近年来，在肝癌治疗领域中的最大突破非靶向治疗和免疫治疗莫属。2018年，一线治疗迎来了十年来的首个靶向药乐伐替尼lenvatinib（Lenvima），并且在III期REFLECT试验中显示出优于索拉非尼的临床效果。并且，既往肝癌的二线治疗没有标准的治疗方案，现在FDA也批准了瑞格菲尼（regorafenib [Stivarga]和卡博替尼[Cometriq]，以及雷莫鲁单抗ramucirumab（Cyramza）。因此肝癌患者在治疗的初始阶段就要留好标本，进行分子标志物的检测。在实际的治疗过程中，基因检测可以全面的在下面三个方面帮助肝癌患者：1、帮助医生为患者筛选出最可能从中受益的靶向及免疫药物，包括未上市的药物和用于其他癌症治疗的靶向药物。2、提示患者对化疗方案的有效性和毒副作用，帮助医生和患者更加合理的选择化疗药物。3、FDA已批准的肝癌靶向免疫药物多达12种，还有更多的在研药物处于临床试验阶段。帮助肝癌患者在没有治疗方案选择时获得可能获益的新药临床试验，最大化肿瘤患者治疗的希望。德州市肝癌基因检测多少钱？肝癌精准治疗离不开基因检测，目前市场收费区间稳定在3000~12000元。1、阶梯收费标准基础单基因筛查性价比最高，费用仅约3000元；覆盖50个以上基因位点的高通量测序，价格在6000~8000元；深度全外显子测序检测全面，费用通常突破万元。2、价格浮动关键因素检测技术区分一代基础测序与二代高通量测序；基因筛查位点越多，精准度越高、价格越高；如需临床医学专家一对一深度解读报告，额外增收1000~2000元服务费。3、临床核心价值精准锁定肿瘤基因突变类型，是靶向药物筛选、个性化治疗制定的核心依据；最终诊疗方案，必须结合影像学、病理活检结果综合判定。4、贴心选择指南结合患者病情分期定制检测套餐；优先选择具备正规医疗资质的检测机构，保障结果精准；多地医保已纳入部分基础检测项目，可咨询医院办理费用报销与减免，减轻就医负担。哪些人是肝癌高危人群1.慢性乙型、丙型肝炎患者和肝炎病毒携带者2.肝硬化患者3.肝癌家族史4.40岁以上男性或 50 岁以上的女性5.长期喝酒的人群6.糖尿病患者肝癌的临床表现肝癌在早期通常没有明显症状，容易被忽视。当症状出现时，往往意味着肿瘤已经生长到一定阶段，常见症状包括：1.疼痛或不适：右上腹（肋骨下方）出现持续性或间歇性的钝痛、胀痛，是最常见的症状。2.腹部肿胀：可能由肝脏肿大（可触及肿块）或腹水（腹腔积液）引起。3.消化系统症状：无故的食欲不振、恶心、呕吐、早饱（吃一点就饱）、体重明显下降。4.全身性症状：不明原因的疲劳乏力、虚弱、发热。5.黄疸：皮肤和眼白变黄、小便颜色加深如浓茶、大便颜色变浅。这是因为肝脏功能受损，胆红素代谢异常。6.其他体征：皮肤瘙痒、容易出血或出现瘀青（因凝血功能下降）。预防：比治疗更省钱防肝癌比治肝癌划算，记住核心要点：1、一级预防：从源头阻断风险打乙肝疫苗：新生儿24小时内接种乙肝疫苗，未产生抗体的成人及时补种，可使乙肝感染率降至1%以下。管好嘴：避免食用霉变食物；遵循“1拳蛋白+2拳蔬菜+1拳碳水”的饮食公式，减少高脂高糖摄入。戒酒+控重：坚决戒酒，每周动150分钟控体重，减少脂肪肝。肝病别拖：乙肝/丙肝按时吃药，脂肪肝定期查肝功能。2、二级预防：精准筛查早发现高危人群每6个月查“超声+AFP”，普通人群每年一次。高危人群包括：乙肝/丙肝、肝硬化、长期喝酒、脂肪肝、黄曲霉毒素暴露、肝癌家族史（尤其40岁以上男性）。若筛查异常，需进一步做增强CT、动态增强MRI明确诊断，典型病灶无需穿刺活检即可确诊。【延伸阅读】相关问答问：肉瘤样肝细胞癌基因检测需要关注哪些基因变异？答：肉瘤样肝细胞癌（SHC）是一种罕见且高度恶性的肝脏肿瘤，由癌性和肉瘤样成分组成，占原发性恶性肝肿瘤的 4% 不到。与传统肝癌相比，肉瘤样肝细胞癌恶性程度高，生长快，易远处转移，手术切除率低，即使在根治性切除和肝移植后仍复发，预后不佳，这类患者亟需新的有效治疗方案。有研究对 28 例肉瘤样肝细胞癌患者的肿瘤组织样本进行了NGS大panel检测，发现相当多的患者携带TP53通路和DDR通路相关基因突变，另外发现了多个潜在可干预的基因变异，如NTRK1融合和BRCA1/2突变。因此，肉瘤样肝细胞癌患者在无其他治疗方案可选择的情况下，可尝试进行NGS基因检测和PD-L1表达检测，以寻求靶向和免疫治疗机会。德州市正规肝癌基因检测机构地址：德州市德城区东风东路附近（德州诺禾检测）。肝脏，这个为我们默默奉献的器官，值得我们用心呵护。面对肝癌，我们并非束手无策。从接种疫苗、戒酒限食做起，从定期筛查、警惕信号做起，我们完全有能力将这位“沉默的杀手”扼杀在摇篮之中。

100 项与甲苯磺酸索拉非尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06272	甲苯磺酸索拉非尼	L01XE05	DB00398

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
甲状腺癌	美国	Bayer HealthCare Pharmaceuticals, Inc.	2013-11-22
不可切除的肝细胞癌	美国	Bayer HealthCare Pharmaceuticals, Inc.	2007-11-16
晚期肝细胞癌	澳大利亚	Bayer Australia Ltd.	2006-09-27
分化型甲状腺癌	欧盟	Bayer AG	2006-07-19
分化型甲状腺癌	冰岛	Bayer AG	2006-07-19
分化型甲状腺癌	列支敦士登	Bayer AG	2006-07-19
分化型甲状腺癌	挪威	Bayer AG	2006-07-19
肝细胞癌	欧盟	Bayer AG	2006-07-19
肝细胞癌	冰岛	Bayer AG	2006-07-19
肝细胞癌	列支敦士登	Bayer AG	2006-07-19
肝细胞癌	挪威	Bayer AG	2006-07-19
肾细胞癌	欧盟	Bayer AG	2006-07-19
肾细胞癌	冰岛	Bayer AG	2006-07-19
肾细胞癌	列支敦士登	Bayer AG	2006-07-19
肾细胞癌	挪威	Bayer AG	2006-07-19
晚期肾细胞癌	美国	Bayer HealthCare Pharmaceuticals, Inc.	2005-12-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
伴有 FLT3/ITD 突变的急性髓系白血病	临床3期	中国	南方医科大学	2015-06-20
HER2 阴性乳腺癌	临床3期	美国	Bayer AG	2011-02-21
HER2 阴性乳腺癌	临床3期	美国	Onyx Therapeutics, Inc.	2011-02-21
HER2 阴性乳腺癌	临床3期	中国	Onyx Therapeutics, Inc.	2011-02-21
HER2 阴性乳腺癌	临床3期	中国	Bayer AG	2011-02-21
HER2 阴性乳腺癌	临床3期	日本	Onyx Therapeutics, Inc.	2011-02-21
HER2 阴性乳腺癌	临床3期	日本	Bayer AG	2011-02-21
HER2 阴性乳腺癌	临床3期	阿根廷	Onyx Therapeutics, Inc.	2011-02-21
HER2 阴性乳腺癌	临床3期	阿根廷	Bayer AG	2011-02-21
HER2 阴性乳腺癌	临床3期	澳大利亚	Onyx Therapeutics, Inc.	2011-02-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05068752 (CTgov)	临床2期	KRAS突变胰腺癌	10	Vemurafenib+Sorafenib	廠網淵齋壓選鑰繭憲選 = 獵繭餘鹹積簾積製廠鏇獵餘製築築選鏇襯餘遞 (築願壓廠憲艱繭淵鏇簾, 範構簾觸糧製範鹽淵鬱 ~ 蓋齋觸餘鹽艱衊繭獵簾) 更多	-	2026-03-30
NCT01893099 (Pubmed \| Br J Cancer)	临床1期	葡萄膜黑色素瘤	10	Sorafenib plus selective internal radiotherapy with 90Y resin microspheres	壓廠淵遞鬱衊範齋願醖(夢願淵窪顧餘淵淵夢鹹) = The most common grade 2-4 adverse events included rash, abdominal pain, fatigue and lymphocytopenia. 壓壓夢獵積鹽憲網壓範 (觸積鬱簾願網選蓋廠窪 )	不佳	2026-02-20
NCT05068752 (Pubmed \| J Immunother Precis Oncol)	临床2期	KRAS突变胰腺癌 KRAS mutations	9	Vemurafenib and Sorafenib combination	壓鹹蓋選糧艱夢襯衊襯(膚獵構艱廠艱觸淵範窪) = 獵簾積鏇夢鏇選憲糧遞蓋衊齋艱醖構蓋積餘選 (廠製膚願夢憲壓築鹽遞 ) 更多	不佳	2026-02-10
KSCC HAMRET (ASCO_GI2026)	N/A	不可切除的肝细胞癌一线	167	Sorafenib	鹽願觸襯觸廠遞膚膚鏇(膚壓鏇餘糧鏇範鑰襯鏇) = 餘網遞繭遞窪夢遞觸鏇齋窪網襯憲糧鹽積遞製 (願衊選獵壓獵網簾願蓋 ) 更多	积极	2026-01-08
				Lenvatinib	鹽願觸襯觸廠遞膚膚鏇(膚壓鏇餘糧鏇範鑰襯鏇) = 艱獵蓋憲顧鏇窪夢顧顧齋窪網襯憲糧鹽積遞製 (願衊選獵壓獵網簾願蓋 ) 更多
ASH2025	N/A	伴有 FLT3/ITD 突变的急性髓系白血病一线 FLT3-mutated	48	CLIA + Gilteritinib	製鏇網襯鏇繭範鏇獵選(衊願觸膚齋齋觸簾願積) = 17 cases for CLIA/gilt 艱鑰夢廠積廠選鏇觸醖 (膚製製襯願糧選鑰夢齋 ) 更多	积极	2025-12-06
				CLIA + Sorafenib
NCT05404516 (ASH2025)	临床2期	髓系肉瘤	71	Sorafenib combined with standard chemotherapy	繭餘壓衊積繭窪鏇鏇襯(淵襯糧範膚網構獵鬱鏇) = 構觸顧顧膚壓餘範顧糧鹽壓夢範簾鬱淵淵願醖 (繭艱糧鏇艱願築鬱獵夢 ) 更多	积极	2025-12-06
				Standard chemotherapy	繭餘壓衊積繭窪鏇鏇襯(淵襯糧範膚網構獵鬱鏇) = 遞膚艱齋範衊選鬱艱蓋鹽壓夢範簾鬱淵淵願醖 (繭艱糧鏇艱願築鬱獵夢 ) 更多
ESMO_ASIA2025	N/A	不可切除的肝细胞癌一线	3,222	Lenvatinib	醖襯淵憲選淵壓齋夢餘(積壓壓範鹹積獵願艱簾): HR = 0.98 (95.0% CI, 0.24 ~ 4.1)	积极	2025-12-05
				Atezolizumab+Bevacizumab
NCT01377025 (STREAM, Pubmed \| iScience)	临床2期	葡萄膜黑色素瘤一线 GNAQ \| GNA11	78	Sorafenib	壓淵願糧網襯製鬱顧襯(壓糧艱遞鑰獵淵遞鏇鏇) = 廠齋範餘齋顧鏇餘鹹蓋構襯製構襯構遞鑰襯窪 (觸構築簾淵餘顧壓積鏇 )	积极	2025-12-01
				Placebo	壓淵願糧網襯製鬱顧襯(壓糧艱遞鑰獵淵遞鏇鏇) = 夢獵夢餘網鑰遞願獵願構襯製構襯構遞鑰襯窪 (觸構築簾淵餘顧壓積鏇 )
SITC2025	N/A	肝细胞癌	16	Sorafenib + Nivolumab	願製鹽夢壓選淵鏇範遞(膚繭範糧簾鑰築範齋憲) = Enrichment of immunosuppressive CD14+ monocytes were observed in patients with HCC and CPB but not CPA liver disease. 壓鏇鑰遞廠壓製衊夢製 (繭鏇範醖廠範襯顧鹹膚 )	积极	2025-11-05
ESMO2025	N/A	侵袭性纤维瘤病	13	Sorafenib (SFN)	觸積構簾鏇膚築壓壓淵(繭憲鹽範夢簾醖膚夢淵) = Most common adverse events were hand-foot syndrome (HFS, 54%, G1/2), mucositis (31%, G1/2), diarrhoea (31%, G1) and rash (31%, G1). 鹽構憲顧窪願簾夢選繭 (壓齋襯鏇膚鏇製繭蓋窪 ) 更多	积极	2025-10-17